Authors | Sex | Age | P. ovale subtype (wallikeri/curtisi) | Origin of infection | Time since exposition (days) | Malaria prophylaxis | Malaria naĂ¯ve | Comorbidities | Parasitemia (%) | Antimalarial treatment | Invasive ventilation | Outcome | Ref |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hachimi [10] | M | 31 | NA | Congo | 210 | NA | NA | None | 0.20 | Quinine | Yes | Death | 10 |
Lahlou [11] | NA | NA | NA | NA | NA | NA | NA | History of tuberculosis | 0.20 | Quinine | NA | Death | 9 |
Lau [1] | M | 59 | Curtisi | Nigeria | 180 | Mefloquine | Yes | None | 0.18 | Chloroquine phosphate + primaquine, quinine, artesunate | Yes | Death | 1 |
Rojo-Marcos [12] | M | 43 | NA | Nigeria | 3 | No | No | Hypertension, diabetes | 0.12 | Chloroquine, primaquine | Yes | Survival | 11 |
Rozé [13] | M | 24 | NA | Chad ivory coast | NA | Doxycycline | NA | Tuberous sclerosis | 0.20 | Chloroquine, quinine | No | Survival | 12 |